MN553 / MN553: Advanced Pharmacology & Pharmacotherapeutics Quiz 9 Questions & Answers

MN553 Advanced Pharmacology & Pharmacotherapeutics Quiz 9



Question i1 1 i/ i1 ipoint
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
i i i i i i i i i i



Question options:
i i




i i i i i i i i i i i i i i i i ii A ineed ito imonitor idrugs imetabolized iby i2D6 ifor itoxicity
Increased dosages needed of drugs metabolized by 2D6, such as the selective
serotonin reuptake inhibitors
Decreased iconversion iof icodeine ito imorphine iby iCYP i2D6
The ineed ifor ilowered idosages iof idrugs, isuch ias ibeta iblockers
Question i1 i/ i1

2i point
Rifampin is a nonspecific CYP450 inducer that may:
i i i i i i i



Question options:
i i




i i i i i i i i i i i i i i i i ii Lead ito itoxic ilevels iof irifampin iand imust ibe imonitored iclosely
i i i i i i i i i i i i i i i i ii Cause itoxic ilevels iof idrugs, isuch ias ioral icontraceptives, iwhen icoadministered
Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
failure
Cause inonspecific ichanges iin idrug imetabolism
Question 1 i/ i1
3i point
i


Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
i i i i i i i i i i i



Question options:
i i




i i i i i i i i i i i i i i i i ii Decreased itherapeutic ilevels iof iquinidine
i Increased itherapeutic ilevels iof iquinidine
i i i i i i i i i i i i i ii



Decreased ilevels iof ia icoadministered idrug, isuch ias idigoxin, ithat irequires iP-
glycoprotein ifor iabsorption iand ielimination
Increased levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
Question 1 i/ i1
i4 ipoint


Warfarin resistance may be seen in patients with VCORC1 mutation, leadingto:
i i i i i i i i i i i

, Question options: i




i i i i i i i i i i i i i i i i ii Toxic ilevels iof iwarfarin ibuilding iup
Decreased response to warfarin
Increased irisk ifor isignificant idrug iinteractions iwith iwarfarin
Less irisk iof idrug iinteractions iwith iwarfarin
Question i1 i/ i1

5i point
Pharmacogenetic testing is required by the U.S. Food and Drug i i i i i i i i i


Administration prior to prescribing:
i i i i



Question options: i




i i i i i i i i i i i i i i i i ii Erythromycin
Digoxin
i



Cetuximab
Rifampin
Question 1 i/ i1
6i ipoint


Carbamazepine has a Black Box Warning recommending testing for the
i i i i i i i i i


HLA-B*1502 allele in patients with Asian ancestry prior to starting therapy
i i i i i i i i i i i


due to:
i i



Question options: i



Decreased ieffectiveness iof icarbamazepine iin itreating iseizures iin iAsian ipatients iwith
ithe iHLA-B*1502 iallele



i i i i i i i i i i i i i i i i ii Increased irisk ifor idrug iinteractions iin iAsian ipatients iwith ithe iHLA-B*1502 iallele
Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502
Allele
Patients iwho ihave ithe iHLA-B*1502 iallele ibeing imore ilikely ito ihave ia iresistance ito
icarbamazepine


Question 1 i/ i1
7i ipoint


A genetic variation in how the metabolite of the cancer drug irinotecan SN-38is
i i i i i i i i i i i i i


inactivated by the body may lead to:
i i i i i i i



Question options: i